# AdvanCell

> AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies (TAT) for cancer, powered by its proprietary Lead-212 (212Pb) alpha isotope generator technology. By solving the chronic supply bottleneck of alpha-emitting isotopes, AdvanCell aims to deliver highly potent, tumor-specific radiation that destroys cancer cells while sparing healthy tissue. Its lead asset, ADVC001, a 212Pb-PSMA therapy, is in clinical trials for metastatic prostate cancer, with a deepening pipeline targeting melanoma, ovarian, breast, and lung cancers.

- **Founded:** 2019
- **Headquarters:** Brisbane, Australia (US HQ: Cambridge, Massachusetts)
- **Founders:** Andrew Adamovich (Founder & former CEO; now Managing Director, Australia and Board member)
- **Team size:** ~85 employees (company has cited ~60 during 2025; growing)
- **Products:** ADVC001 (212Pb-PSMA), ADVC002, ADVC003, Alpha Isotope Generator Technology
- **Notable:** Completed an oversubscribed US$112M Series C in February 2025, backed by Sanofi Ventures, SV Health Investors, Abingworth and others., Built a 40,000-square-foot GMP manufacturing facility in Brisbane with proprietary Lead-212 generator technology., Received first delivery of high-activity Thorium-228, a rare capability essential to scaling Lead-212 production.

## Products & services

- **ADVC001 (212Pb-PSMA)** — Lead asset; a Lead-212-based PSMA-targeted alpha therapy in Phase 1b/2a clinical trials for metastatic castration-resistant prostate cancer, now advancing into a Phase 2 expansion trial (TheraPb).
- **ADVC002** — Targeted alpha therapy candidate in development for melanoma.
- **ADVC003** — Targeted alpha therapy candidate in development for ovarian, breast, and lung cancers.
- **Alpha Isotope Generator Technology** — Proprietary 212Pb production platform that generates a scalable, GMP supply of Lead-212 from Thorium-228, addressing a key isotope supply-chain bottleneck for the entire TAT field.

## Achievements

- Completed an oversubscribed US$112M Series C in February 2025, backed by Sanofi Ventures, SV Health Investors, Abingworth and others.
- Built a 40,000-square-foot GMP manufacturing facility in Brisbane with proprietary Lead-212 generator technology.
- Received first delivery of high-activity Thorium-228, a rare capability essential to scaling Lead-212 production.
- Presented encouraging Phase 1b clinical data for ADVC001 in prostate cancer at ESMO 2025.
- Initiated the TheraPb Phase 2 expansion trial of ADVC001.
- Appointed Philina Lee, PhD as CEO to lead US expansion (effective Jan 1, 2026).

## Latest updates

- **2025-02** — Closed oversubscribed US$112M Series C financing to fund targeted alpha radiopharma trials.
- **2025-10** — Presented promising Phase 1b clinical trial results for ADVC001 at ESMO 2025.
- **2025-11** — Appointed Philina Lee, PhD as CEO to lead US expansion and global growth.
- **2025-12** — Initiated Phase 2 expansion (TheraPb) trial of ADVC001 in metastatic prostate cancer; received first high-activity Thorium-228 delivery.

## Links

- Website: https://advancell.com.au
- LinkedIn: https://www.linkedin.com/company/advancell
- Twitter/X: https://twitter.com/AdvanCell_Iso
- Facebook: https://facebook.com/advancellisotopes/

---

Profile page: https://yespress.io/advancell
Published by YesPress — https://yespress.io
Last updated: 2026-06-10